A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. (opens ClinicalTrials.gov)
- Sponsor
- Natera, Inc.
- Enrolment
- 920
- Started
- 2027-01
- Last update
- 2026-10-27
Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC…
Interventions: Signatera Genome ultra-sensitive ctDNA blood test